Drug Profile
Research programme: osteoporosis therapeutics - Fulcrum
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Fulcrum Pharmaceuticals
- Class Small molecules
- Mechanism of Action Osteoclast inhibitors; RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoporosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoporosis in USA (PO)
- 23 Jun 2004 Preclinical trials in Osteoporosis in USA (PO)